Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) announced the successful completion of a pilot project with Kuano Ltd. that leverages artificial intelligence and quantum-based computational analysis to advance the company’s PNKP Inhibitor Technology (ONC010). The project delivered molecular modeling and computational findings that strengthen Onco’s understanding of how its PNKP inhibitor and related analogs interact with the target, producing a refined structural hypothesis for PNKP inhibition and establishing a framework for structure-based optimization and future evaluation.
The collaboration applied quantum-based computational methods to assess PNKP structural behavior and develop human PNKP structural models for follow-on analysis. According to the company, the results are expected to support future initiatives including quantum-based QSAR modeling, toxicity mapping, and AI-assisted generative compound design. These advancements aim to improve compound prioritization and accelerate progress toward preclinical development for solid tumour treatments. The full press release is available at https://ibn.fm/SdQqD.
Onco-Innovations is a Canadian-based company focused on cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco has secured an exclusive worldwide license to patented technology targeting solid tumours. This pilot project represents a critical step in advancing its pipeline toward clinical applications.
The integration of AI and quantum computing in drug discovery offers significant implications for the efficiency and accuracy of compound development. By applying these advanced computational techniques, Onco-Innovations aims to reduce the time and cost associated with traditional preclinical research. This approach could potentially lead to more effective therapies for solid tumours, addressing a major unmet medical need in oncology.
For more information and updates regarding ONNVF, visit the company’s newsroom at https://ibn.fm/ONNVF. The successful completion of this pilot project highlights the growing role of computational methods in biopharmaceutical research and positions Onco-Innovations to leverage these technologies for future drug development.
